Toggle Main Menu Toggle Search

Open Access padlockePrints

Patient Preferences in Rare Diseases: A Qualitative Study in Neuromuscular Disorders to Inform a Quantitative Preference Study

Lookup NU author(s): Dr Cecilia Jimenez Moreno, Professor Grainne Gorman



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


© 2021, The Author(s).Introduction: It has become increasingly important to include patient preference information in decision-making processes for drug development. As neuromuscular disorders represent multisystem, debilitating, and progressive rare diseases with few treatment options, this study aimed to explore unmet health care needs and patient treatment preferences for two neuromuscular disorders, myotonic dystrophy type 1 (DM1) and mitochondrial myopathies (MM) to inform early stages of drug development. Methods: Fifteen semi-structured interviews and five focus group discussions (FGDs) were held with DM1 and MM adult patients and caregivers. Topics discussed included (1) reasons for study participation; (2) disease signs/symptoms and their impact on daily lives; (3) top desired benefits; and (4) acceptability of risks and tolerance levels for a hypothetical new treatment. Data were analyzed following a thematic ‘code’ approach. Results: A total of 52 participants representing a wide range of disease severities participated. ‘Muscle strength’ and ‘energy and endurance’ were the disease-related unmet needs most often mentioned. Additionally, improved ‘balance’, ‘cognition’ and ‘gut function’ were the top desired treatment benefits, while ‘damage to the liver, kidneys or eyes’ was the most concerning risk. Factors influencing their tolerance to risks related to previously having experienced the risk and differentiation between permanent and temporary risks. A few differences were elicited between patients and caregivers. Conclusions: This qualitative study provided an open forum to elicit treatment-desired benefits and acceptable risks to be established by patients themselves. These findings can inform decisions for developing new treatments and the design of clinical trials for DM1 and MM.

Publication metadata

Author(s): Jimenez-Moreno AC, van Overbeeke E, Pinto CA, Smith I, Sharpe J, Ormrod J, Whichello C, de Bekker-Grob EW, Bullok K, Levitan B, Huys I, de Wit GA, Gorman G

Publication type: Article

Publication status: Published

Journal: Patient

Year: 2021

Volume: 14

Issue: 5

Pages: 601-612

Print publication date: 01/09/2021

Online publication date: 27/02/2021

Acceptance date: 13/11/2020

Date deposited: 25/08/2021

ISSN (print): 1178-1653

ISSN (electronic): 1178-1661

Publisher: Adis


DOI: 10.1007/s40271-020-00482-z

PubMed id: 33660162


Altmetrics provided by Altmetric


Funder referenceFunder name
supported by MDUK, the MDSG and the Lily Foundation